Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma.
|
31405179 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mortalin, an hsp70 chaperone protein, is overexpressed in various cancer, including HCC.
|
30628118 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that genetic ablation of HSP70 markedly impairs HCC initiation and progression by distinct but overlapping pathways.
|
30745413 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of this study were to: validate the use of the immunohistochemical (IHC) markers glutamine synthetase (GS), glypican-3 (GPC3), heat shock protein-70 (HSP70) and enhancer of zeste homologue 2 (EZH2) in liver biopsies for the differential diagnosis between small hepatocellular carcinoma (HCC) and non-neoplastic liver nodules, with special attention to <10-mm nodules; and assess the actual sensitivity and specificity of the single markers, and their combination, in needle biopsies.
|
28881044 |
2018 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, HSP70 is a key regulator involved in the proliferation, migration and invasion of HCC, and it may be used as a potential therapeutic target for HCC.
|
28928813 |
2017 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extracellular HSP70/HSP70-PCs regulate hepatocarcinoma cell migration and invasion via RhoA.
|
28454219 |
2017 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we evaluated expression of DAMP proteins HSP70 and cancer-testis antigen SPAG9 in patients with hepatocellular carcinoma (HCC) and lung cancer to explore tumor immunity.
|
28028759 |
2017 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicated that a vaccination therapy using DCs co-pulsed with the Hsp70/HBxAg complex is an effective strategy for immunotherapy and may offer a useful approach to protect against HCC.
|
26647961 |
2016 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The molecular mechanisms of HSP70/HSP70-PC action were studied in the human hepatocellular carcinoma cell lines HepG2 and Huh-7, as well as tumor tissue collected from patients with HCC (n = 95).
|
27492456 |
2016 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucose, but not 2D-glucose, can induce the phosphorylation of HSF1 at S326 and upregulate the expression of HSF1's downstream alpha B-crystallin and Hsp70 as well as the none-heat shock proteins CSK2 and RBM23 in two tested hepatocellular carcinoma cell lines (prl/prf5 and SMMC7721).
|
26010766 |
2015 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sensitivity and specificity for HCC diagnosis were: 50.9% and 98.9% for P53, and 78.2 and 77.8% for HSP70, respectively.
|
26494212 |
2015 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The high expression of HSPA4 (HR = 1.002, 95% CI = 1.000-1.004, P = 0.019), HSPA5 (HR = 1.0, 95% CI = 1.0-1.0, P = 0.046) and HSPA6 (HR = 1.008, 95% CI = 1.001-1.015, P = 0.021) was similarly associated with HCC recurrence.
|
25798051 |
2015 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that when combined with cancer cell apoptosis, anticancer drugs induce the membrane expression and release of HSP70/gp96 in hepatocellular carcinoma (HCC) cells, which may represent a crucial event in the immune anti-tumour response.
|
25955691 |
2015 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggested that HSP70 could be a molecular target for treatment of HCC.
|
25982372 |
2015 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, to verify the targeting and effectiveness of the therapeutic strategy using a Survivin promoter-regulated oncolytic adenovirus expressing Hsp70, the PDTX models of hepatocellular carcinoma (HCC) were established in nude mice and the cytokine-induced killer (CIK) cells were intravenously infused into mice to partially reconstruct the mouse immune function.
|
25473902 |
2015 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, expression of 14-3-3σ significantly correlates with HSF-1α/HSP70 in HCC tumors and both 14-3-3σ and HSP70 overexpression are associated with micro-vascular thrombi in HCC patients, suggesting that 14-3-3σ/HSP70 expression is potentially involved in cell migration/invasion.
|
24923353 |
2014 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several recently characterized immunohistochemical markers such as glypican-3 (GPC-3), heat-shock protein-70 (HSP-70), and glutamine synthetase (GS) help distinguish dysplastic nodules from HCC.
|
22914605 |
2013 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HSP70 promoted the proliferation of H22 hepatocarcinoma cells through Toll-like receptor (TLR) 2 and TLR4 signaling and induced the early phosphorylation of NF-κB, which reached maximum levels within 30 min.
|
23836405 |
2013 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glutamine synthetase (GS), heat shock protein-70 (HSP-70), and glypican-3 (GPC-3) are markers best characterized in hepatocellular lesions, where they are useful in distinguishing hepatocellular carcinoma from dysplastic nodules.
|
22914614 |
2013 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several genes, such as HSP70, CAP2 and GPC3, have been identified as potential biomarkers for early human hepatocellular carcinoma.
|
20603246 |
2010 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Expression of the Hsp110 family members was further analyzed, and increased transcript levels of Hsp110 and Apg-2, but not Apg-1, were found in 12 and 14, respectively, of 18 HCCs.
|
14987991 |
2004 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Apg-2 has a chaperone-like activity similar to Hsp110 and is overexpressed in hepatocellular carcinomas.
|
14987991 |
2004 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, HSP70 could be a sensitive marker for the differential diagnosis of early HCC from precancerous lesion or noncancerous liver, a difficult distinction for pathologists due to very well differentiated histology with little atypia in early HCC.
|
12500205 |
2003 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of hsp70-the inducible member of the corresponding heat shock gene family-of the oxidative stress marker gene heme oxygenase (HOx), and of the immediate early response genes c-fos and c-jun has been studied in FAO hepatocarcinoma cells depleted of polyamines and exposed to heat shock.
|
8707255 |
1996 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By heat shock, hsp70 mRNA was induced in all three hepatoma lines, Hep G2, Hep 3B and Hep G2f, while heme oxygenase mRNA was increased only in Hep 3B.
|
2154980 |
1990 |